Clinical Trial Update: Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating ZGB (zanubrutinib, obinutuzumab, bendamustine) as first-line therapy for chronic lymphocytic leukemia; the study is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Gazyva (Obinutuzumab)
• Treanda (Bendamustine)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: NOT_YET_RECRUITING